Lymphome du manteau : prise en charge 2011

[fr] Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14, avec surexpression de la cycline D1. Le traitement de première ligne du sujet jeune associe trois cures de R-CHOP21 alternées avec trois cures de R-DHAP21, suivies d'une autogreffe conditionnée par irradiation corporelle totale, cyclophosphamide et aracytine. Le sujet de plus de 65 ans peut bénéficier de huit cures de R-CHOP21. L'intérêt du traitement de maintenance est en cours d'évaluation. L'allogreffe de cellules souches hématopoïétiques offre une chance de guérison aux patients en rechute en bon état général. Les traitements ciblés permettront une amélioration du pronostic de cette maladie.

Disciplines :

Hematology

Author, co-author :

Bonnet, Christophe ; Université de Liège - ULiège > GIGA-R : Hématologie

CAERS, Jo ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

DE PRIJCK, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

HAFRAOUI, Kaoutar ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Beguin, Yves ; Université de Liège - ULiège > GIGA-R : Hématologie

Language :

French

Title :

Lymphome du manteau : prise en charge 2011

Publication date :

2011

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Pages :

1644-1649

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 01 February 2012

Statistics

Number of views

271 (6 by ULiège)

Number of downloads

417 (6 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Perez-Galan, P., Dreyling, M., Wiestner, A., Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era (2011) Blood, 117, pp. 26-38
Herrmann, A., Hoster, E., Zwingers, T., Improvement of overall survival in advanced stage mantle cell lymphoma (2009) J Clin Oncol, 27, pp. 511-518
Dreyling, M., Hiddemann, W., Current treatment standards and emerging strategies in mantle cell lymphoma (2009) Hematology Am Soc Hematol Educ Program, pp. 542-551
Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Staudt, L.M., The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma (2003) Cancer Cell, 3 (2), pp. 185-197. , DOI 10.1016/S1535-6108(03)00028-X
Gesk, S., Klapper, W., Martin-Subero, J.I., Nagel, I., Harder, L., Fu, K., Bernd, H.-W., Siebert, R., A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus [5] (2006) Blood, 108 (3), pp. 1109-1110. , http://www.bloodjournal.org/cgi/reprint/108/3/1109, DOI 10.1182/blood-2006-01-0015
Wang, X., Asplund, A.C., Porwit, A., The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: Correlation to overall survival (2008) Br J Haematol, 143, pp. 248-252
Mozos, A., Royo, C., Hartmann, E., SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype (2009) Haematologica, 94, pp. 1555-1562
Jares, P., Colomer, D., Campo, E., Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics (2007) Nature Reviews Cancer, 7 (10), pp. 750-762. , DOI 10.1038/nrc2230, PII NRC2230
Salaverria, I., Zettl, A., Bea, S., Moreno, V., Valls, J., Hartmann, E., Ott, G., Campo, E., Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature (2007) Journal of Clinical Oncology, 25 (10), pp. 1216-1222. , DOI 10.1200/JCO.2006.08.4251
Swerdlow, S.H., Campo, E., Harris, N.L., (2008) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues
Letestu, R., Ugo, V., Valensi, F., Radford-Weiss, I., Nataf, J., Levy, V., Gribben, J.G., Ajchembaum-Cymbalista, F., Prognostic impact of p27KIP1 expression in cyclin D1 positive lymphoproliferative disorders (2004) Leukemia, 18 (5), pp. 953-961. , DOI 10.1038/sj.leu.2403337
A predictive model for aggressive non-Hodgkin's lymphoma. The International non-hodgkin's lymphoma prognostic factors project (1993) N Engl J Med, 329, pp. 987-994
Solal-Celigny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R., Au, W.Y., Montserrat, E., Follicular lymphoma international prognostic index (2004) Blood, 104 (5), pp. 1258-1265. , DOI 10.1182/blood-2003-12-4434
Kienle, D., Krober, A., Katzenberger, T., Ott, G., Leupolt, E., Barth, T.F.E., Moller, P., Stilgenbauer, S., V H mutation status and VDJ rearrangement structure in mantle cell lymphoma: Correlation with genomic aberrations, clinical characteristics, and outcome (2003) Blood, 102 (8), pp. 3003-3009. , DOI 10.1182/blood-2003-05-1383
Walsh, S.H., Thorselius, M., Johnson, A., Soderberg, O., Jerkeman, M., Bjorck, E., Eriksson, I., Rosenquist, R., Mutated V H genes and preferential V H3-21 use define new subsets of mantle cell lymphoma (2003) Blood, 101 (10), pp. 4047-4054. , DOI 10.1182/blood-2002-11-3479
Hoster, E., Dreyling, M., Klapper, W., A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma (2008) Blood, 111, pp. 558-565
Determann, O., Hoster, E., Ott, G., Bernd, H.W., Loddenkemper, C., Hansmann, M.L., Barth, T.E.F., Klapper, W., Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: Results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group (2008) Blood, 111 (4), pp. 2385-2387. , http://bloodjournal.hematologylibrary.org/cgi/reprint/111/4/2385, DOI 10.1182/blood-2007-10-117010
Ghielmini, M., Zucca, E., How I treat mantle cell lymphoma (2009) Blood, 114, pp. 1469-1476
Romaguera, J.E., Medeiros, L.J., Hagemeister, F.B., Fayad, L.E., Rodriguez, M.A., Pro, B., Younes, A., Cabanillas, F., Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma (2003) Cancer, 97 (3), pp. 586-591. , DOI 10.1002/cncr.11096
Juweid, M.E., Stroobants, S., Hoekstra, O.S., Mottaghy, F.M., Dietlein, M., Guermazi, A., Wiseman, G.A., Cheson, B.D., Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of international harmonization project in lymphoma (2007) Journal of Clinical Oncology, 25 (5), pp. 571-578. , http://jco.ascopubs.org/cgi/reprint/25/5/571, DOI 10.1200/JCO.2006.08.2305
Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Diehl, V., Revised response criteria for malignant lymphoma (2007) Journal of Clinical Oncology, 25 (5), pp. 579-586. , http://jco.ascopubs.org/cgi/reprint/25/5/579, DOI 10.1200/JCO.2006.09.2403
Lenz, G., Dreyling, M., Hoster, E., Wormann, B., Duhrsen, U., Metzner, B., Eimermacher, H., Hiddemann, W., Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) (2005) Journal of Clinical Oncology, 23 (9), pp. 1984-1992. , DOI 10.1200/JCO.2005.08.133
Schulz, H., Bohlius, J.E., Trelle, S., Skoetz, N., Reiser, M., Kober, T., Schwarzer, G., Engert, A., Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis (2007) Journal of the National Cancer Institute, 99 (9), pp. 706-714. , DOI 10.1093/jnci/djk152
Ghielmini, M., Schmitz, S.-F.H., Cogliatti, S., Bertoni, F., Waltzer, U., Fey, M.F., Betticher, D.C., Cerny, T., Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss group for clinical cancer research (SAKK) (2005) Journal of Clinical Oncology, 23 (4), pp. 705-711. , DOI 10.1200/JCO.2005.04.164
Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K.H., Neubauer, A., Dolken, G., Von Grunhagen, U., Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German study group hematology and oncology study (2007) Journal of Clinical Oncology, 25 (15), pp. 1986-1992. , DOI 10.1200/JCO.2006.06.4618
Dreyling, M., Lenz, G., Hoster, E., Van Hoof, A., Gisselbrecht, C., Schmits, R., Metzner, B., Hiddemann, W., Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network (2005) Blood, 105 (7), pp. 2677-2684. , DOI 10.1182/blood-2004-10-3883
Hermine, O., Alterning courses of 3X CHOP and 3X DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell tansplantation (ASCT) is superior to 6 couses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Update of results of the MCL younger trial of the mantle cell lymphoma network (MCL NET) (2011) Ann Oncol, , abstract in press
Kluin-Nelemans, J.C., R-CHOP versus R-FC followed by maintenance with rituximab or IFN: First results of randomized trial for elderly patients with mantle cell lymphoma (2011) Ann Oncol, , abstract in press
Martin, P., Chadburn, A., Christos, P., Outcome of deferred initial therapy in mantle-cell lymphoma (2009) J Clin Oncol, 27, pp. 1209-1213
Nickenig, C., Dreyling, M., Hoster, E., Pfreundschuh, M., Trumper, L., Reiser, M., Wandt, H., Hiddemann, W., Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (2006) Cancer, 107 (5), pp. 1014-1022. , DOI 10.1002/cncr.22093
Cheson, B.D., Rummel, M.J., Bendamustine: Rebirth of an old drug (2009) J Clin Oncol, 27, pp. 1492-1501
Lefrere, F., Delmer, A., Levy, V., Delarue, R., Varet, B., Hermine, O., Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study (2004) Haematologica, 89 (10), pp. 1275-1276
Romaguera, J.E., Fayad, L.E., Feng, L., Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyper-CVAD alternating with rituximab-high dose methotrexate/ cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma (2010) Br J Haematol, 150, pp. 200-208
Romaguera, J.E., Fayad, L., Rodriguez, M.A., High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high dose methotrexate and cytarabine (2005) J Clin Oncol, 23, pp. 7013-7023
Khouri, I.F., Romaguera, J., Kantarjian, H., Palmer, J.L., Pugh, W.C., Korbling, M., Hagemeister, F., Champlin, R., Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma (1998) Journal of Clinical Oncology, 16 (12), pp. 3803-3809
Dreyling, M., Polliack, A., Tadmor, T., Chlorambucil in indolent mantle cell lymphoma - Just another old drug for a new disease? (2011) Leuk Lymphoma, 52, pp. 351-352
Pott, C., Hoster, E., Delfau-Larue, M.H., Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study (2010) Blood, 115, pp. 3215-3223
Wang, M., Oki, Y., Pro, B., Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma (2009) J Clin Oncol, 27, pp. 5213-5218
Goy, A., Bernstein, S.H., Kahl, B.S., Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study (2009) Ann Oncol, 20, pp. 520-525
Hess, G., Herbrecht, R., Romaguera, J., Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma (2009) J Clin Oncol, 27, pp. 3822-3829